摘要
目的探讨罗沙司他治疗肾性贫血的临床疗效及其对炎性因子的影响。方法选取团风县中医医院2018年3月—2020年3月收治的肾性贫血患者72例,根据抽签方法分为对照组与观察组,各36例。对照组予以常规治疗,观察组在对照组基础上加用罗沙司他治疗。2组均连续治疗3个月。比较2组临床疗效,治疗前后炎性因子[C反应蛋白(CRP)、白介素6(IL-6)]、贫血相关指标(红细胞计数、血红蛋白以及血细胞比容)、铁代谢指标[血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、转铁蛋白(TRF)以及铁调素(Hepc)],并观察2组不良反应发生情况。结果观察组治疗总有效率高于对照组(P<0.05)。治疗前2组CRP、IL-6、红细胞计数、血红蛋白以及血细胞比容比较,差异无统计学意义(P>0.05);治疗后观察组CRP、IL-6低于对照组,红细胞计数、血红蛋白以及血细胞比容高于对照组(P<0.05)。治疗前2组SF、TSAT、TRF、Hepc比较,差异无统计学意义(P>0.05);治疗后观察组SF、TSAT、TRF高于对照组,Hepc低于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论罗沙司他治疗肾性贫血的临床疗效确切,可有效调节铁代谢,纠正贫血,避免炎性因子对机体的损伤,且安全性较高。
Objective To analyze the clinical efficacy and impact on inflammatory factor of roxastatin in the treatment of renal anemia.Methods A total of 72 cases of patients with renal anemia were selected from March 2018 to March 2020 in Tuanfeng County Hospital of Traditional Chinese Medicine,which were divided into control group and observation group according to the method of drawing lots,36 cases in each group.The control group was given routine treatment,the observation group was treated with roxastatin on the basis of the control group.Both groups were treated continuously for 3 months.Clinical efficacy,inflammatory factors(CRP,IL-6),anemia related indicators(red blood cell count,hemoglobin and hematocrit),iron metabolism indicators(SF,TSAT,TRF and Hepc)before and after treatment were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate of observation group was higher than that of control group(P<0.05).Before treatment,there was no significant difference in CRP,IL-6,red blood cell count,hemoglobin and hematocrit between the two groups(P>0.05);after treatment,the observation group of CRP,IL-6 were lower than control group,while red blood cell count,hemoglobin and hematocrit were higher than control group(P<0.05).Before treatment,there was no significant difference in SF,TSAT,TRF and Hepc between the two groups(P>0.05);after treatment,SF,TSAT and TRF in observation group were higher than those in control group,while Hepc was lower than that in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05).Conclusion Roxastatin have an exact clinical effect for renal anemia,which can effectively regulate iron metabolism,correct anemia,and avoid the damage of inflammatory factors to the body,and with high safety.
作者
余桂芳
王涛
王少元
YU Guifang;WANG Tao;WANG Shaoyuan(Tuanfeng County Hospital of Traditional Chinese Medicine,Huanggang 438800,China)
出处
《临床合理用药杂志》
2021年第24期35-37,40,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
肾性贫血
罗沙司他
炎性因子
治疗结果
Renal anemia
Rosalstatin
Inflammatory factor
Treatment outcome
